Joel B. Schachter

3.0k total citations
35 papers, 2.0k citations indexed

About

Joel B. Schachter is a scholar working on Physiology, Molecular Biology and Physiology. According to data from OpenAlex, Joel B. Schachter has authored 35 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 15 papers in Molecular Biology and 13 papers in Physiology. Recurrent topics in Joel B. Schachter's work include Alzheimer's disease research and treatments (13 papers), Adenosine and Purinergic Signaling (13 papers) and Receptor Mechanisms and Signaling (9 papers). Joel B. Schachter is often cited by papers focused on Alzheimer's disease research and treatments (13 papers), Adenosine and Purinergic Signaling (13 papers) and Receptor Mechanisms and Signaling (9 papers). Joel B. Schachter collaborates with scholars based in United States, Germany and China. Joel B. Schachter's co-authors include Robert A. Nicholas, T. Kendall Harden, José L. Boyer, Lit‐Fui Lau, Thomas A. Lanz, K. Richter, R. Kyle Palmer, Michaeline Hebron, Irina Lonskaya and Charbel Moussa and has published in prestigious journals such as Journal of Neuroscience, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Joel B. Schachter

34 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel B. Schachter United States 24 860 783 682 461 222 35 2.0k
Susan Boyce United Kingdom 18 825 1.0× 842 1.1× 276 0.4× 627 1.4× 211 1.0× 24 2.0k
Nicole Mahy Spain 32 896 1.0× 566 0.7× 269 0.4× 976 2.1× 149 0.7× 91 2.6k
Fabio Cavaliere Spain 27 610 0.7× 524 0.7× 862 1.3× 693 1.5× 137 0.6× 45 2.2k
Alberto Pérez-Samartı́n Spain 25 926 1.1× 419 0.5× 636 0.9× 973 2.1× 263 1.2× 50 2.9k
Jean‐Guy Chabot Canada 28 889 1.0× 942 1.2× 70 0.1× 1.2k 2.5× 172 0.8× 56 2.3k
Francisco S. Cayabyab Canada 26 935 1.1× 274 0.3× 228 0.3× 454 1.0× 50 0.2× 52 1.9k
David Virley United Kingdom 25 755 0.9× 467 0.6× 78 0.1× 689 1.5× 189 0.9× 51 2.1k
Helena Decker Brazil 14 591 0.7× 1.0k 1.3× 67 0.1× 538 1.2× 229 1.0× 21 1.9k
Masaaki Waragai Japan 30 1.0k 1.2× 1.0k 1.3× 92 0.1× 765 1.7× 155 0.7× 85 3.0k
Gianluca Lozza Italy 15 346 0.4× 174 0.2× 328 0.5× 316 0.7× 60 0.3× 23 951

Countries citing papers authored by Joel B. Schachter

Since Specialization
Citations

This map shows the geographic impact of Joel B. Schachter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel B. Schachter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel B. Schachter more than expected).

Fields of papers citing papers by Joel B. Schachter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel B. Schachter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel B. Schachter. The network helps show where Joel B. Schachter may publish in the future.

Co-authorship network of co-authors of Joel B. Schachter

This figure shows the co-authorship network connecting the top 25 collaborators of Joel B. Schachter. A scholar is included among the top collaborators of Joel B. Schachter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel B. Schachter. Joel B. Schachter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Toolan, Dawn, Sarah Jinn, Joel B. Schachter, et al.. (2021). Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction. Neurobiology of Aging. 106. 12–25. 11 indexed citations
2.
Wang, Xiaohai, Michelle Pearson, Anna C. Hughes, et al.. (2018). Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. PLoS ONE. 13(4). e0195486–e0195486. 23 indexed citations
3.
Usenovic, Marija, et al.. (2018). Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice. Neurobiology of Disease. 118. 161–176. 31 indexed citations
4.
d’Abramo, Cristina, Christopher M. Acker, Joel B. Schachter, et al.. (2015). Detecting tau in serum of transgenic animal models after tau immunotherapy treatment. Neurobiology of Aging. 37. 58–65. 17 indexed citations
5.
Lonskaya, Irina, Michaeline Hebron, Wenqiang Chen, Joel B. Schachter, & Charbel Moussa. (2014). Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. Molecular Neurodegeneration. 9(1). 46–46. 35 indexed citations
6.
Marcus, Jacob & Joel B. Schachter. (2011). Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease. Journal of Neurogenetics. 25(4). 127–133. 38 indexed citations
7.
Helal, Christopher J., Zhijun Kang, Thomas G. Gant, et al.. (2009). Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters. 19(19). 5703–5707. 40 indexed citations
8.
Lanz, Thomas A., Christopher T. Salatto, M. Marconi, et al.. (2007). Peripheral elevation of IGF-1 fails to alter Aβ clearance in multiple in vivo models. Biochemical Pharmacology. 75(5). 1093–1103. 29 indexed citations
9.
10.
Lau, Lit‐Fui, Patricia A. Seymour, Mark A. Sanner, & Joel B. Schachter. (2002). Cdk5 as a Drug Target for the Treatment of Alzheimer's Disease. Journal of Molecular Neuroscience. 19(3). 267–274. 59 indexed citations
11.
Lau, Lit‐Fui, Joel B. Schachter, Patricia A. Seymour, & Mark A. Sanner. (2002). Tau Protein Phosphorylation as a Therapeutic Target in Alzheimers Disease. Current Topics in Medicinal Chemistry. 2(4). 395–415. 49 indexed citations
12.
Schachter, Joel B., et al.. (1997). The 6H1 Orphan Receptor, Claimed to Be the p2y5 Receptor, Does Not Mediate Nucleotide-Promoted Second Messenger Responses. Biochemical and Biophysical Research Communications. 236(2). 455–460. 47 indexed citations
13.
Jiang, Qiaoling, Danping Guo, A. Michiel van Rhee, et al.. (1997). A Mutational Analysis of Residues Essential for Ligand Recognition at the Human P2Y1 Receptor. Molecular Pharmacology. 52(3). 499–507. 114 indexed citations
14.
Schachter, Joel B., José L. Boyer, Qing Li, Robert A. Nicholas, & T. Kendall Harden. (1997). Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C. British Journal of Pharmacology. 122(6). 1021–1024. 48 indexed citations
15.
Herold, Christopher L., Qing Li, Joel B. Schachter, T. Kendall Harden, & Robert A. Nicholas. (1997). Lack of Nucleotide-Promoted Second Messenger Signaling Responses in 1321N1 Cells Expressing the Proposed P2Y Receptor, p2y7. Biochemical and Biophysical Research Communications. 235(3). 717–721. 34 indexed citations
16.
17.
Boyer, José L., Joel B. Schachter, R. Kyle Palmer, et al.. (1996). Avian and human homologues of the P2Y1 receptor: Pharmacological, signaling, and molecular properties. Drug Development Research. 39(3-4). 253–261. 18 indexed citations
18.
Schachter, Joel B., David S. Lester, & Daniel L. Alkon. (1996). Synergistic activation of protein kinase C by arachidonic acid and diacylglycerols in vitro: generation of a stable membrane-bound, cofactor-independent state of protein kinase C activity. Biochimica et Biophysica Acta (BBA) - General Subjects. 1291(2). 167–176. 39 indexed citations
19.
Schachter, Joel B., et al.. (1996). Second messenger cascade specificity and pharmacological selectivity of the human P2Y1‐purinoceptor. British Journal of Pharmacology. 118(1). 167–173. 214 indexed citations
20.
Schachter, Joel B., Robert P. Yasuda, & Barry B. Wolfe. (1995). Adenosine receptor activation potentiates phosphoinositide hydrolysis and arachidonic acid release in DDT1-MF2 cells: Putative interrelations. Cellular Signalling. 7(7). 659–668. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Boyce Breakdown of academic impact, for papers by Nicole Mahy Breakdown of academic impact, for papers by Fabio Cavaliere Breakdown of academic impact, for papers by Alberto Pérez-Samartı́n Breakdown of academic impact, for papers by Jean‐Guy Chabot Breakdown of academic impact, for papers by Francisco S. Cayabyab Breakdown of academic impact, for papers by David Virley Breakdown of academic impact, for papers by Helena Decker Breakdown of academic impact, for papers by Masaaki Waragai Breakdown of academic impact, for papers by Gianluca Lozza
Rankless by CCL
2026